Head to Head Comparison: Ocugen (OCGN) vs. Its Rivals

Ocugen (NASDAQ:OCGN) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Ocugen to similar businesses based on the strength of its dividends, earnings, institutional ownership, analyst recommendations, risk, profitability and valuation.

Valuation and Earnings

This table compares Ocugen and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ocugen	$4.41 million	-$67.85 million	-3.36
Ocugen Competitors	$727.61 million	$12.25 million	-10.38

Ocugen’s competitors have higher revenue and earnings than Ocugen. Ocugen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Ocugen and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Ocugen Competitors	-9,051.23%	-201.20%	-30.64%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ocugen and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1	0	4	0	2.60
Ocugen Competitors	9792	15071	45345	1573	2.54

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 986.34%. As a group, “Biotechnology” companies have a potential upside of 93.67%. Given Ocugen’s stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than its competitors.

Volatility & Risk

Ocugen has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Ocugen’s competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

10.3% of Ocugen shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ocugen competitors beat Ocugen on 7 of the 12 factors compared.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.